医学
荟萃分析
随机对照试验
放射性武器
临床试验
系统回顾
不利影响
外科
梅德林
内科学
政治学
法学
作者
Francesca Veronesi,Simone Ottavio Zielli,Silvia Brogini,Elena Artioli,Alberto Arceri,Antonio Mazzotti,Cesare Faldini,Gianluca Giavaresi
出处
期刊:Bioengineering
[Multidisciplinary Digital Publishing Institute]
日期:2024-09-27
卷期号:11 (10): 970-970
被引量:7
标识
DOI:10.3390/bioengineering11100970
摘要
Scaffolds are widely used devices for the treatment of osteochondral lesions of the talus (OCLT), aimed at enhancing mechanical stability and fostering chondrogenic differentiation. A systematic review and meta-analysis were performed to evaluate the safety, and clinical and radiological results of scaffolds for OCLT management. On 2 January 2024, a search was performed in four databases (PubMed, Embase, Web of Science, and Scopus), according to PRISMA guidelines. The risk of bias in the included studies was also evaluated. Thirty clinical studies were included in the qualitative analysis: 12 retrospective case series, 3 retrospective comparative studies, 9 prospective case series, 1 prospective comparative study, and 1 Randomized Controlled Trial (RCT). Natural scaffolds, such as bilayer collagen (COLL)I/III and hyaluronic scaffolds, were the most employed. Only minor adverse events were observed, even if more serious complications were shown, especially after medial malleolar osteotomy. An overall clinical and radiological improvement was observed after a mean of 36.3 months of follow-up. Patient age and Body Mass Index (BMI), lesion size, and location were correlated with the clinical outcomes, while meta-analysis revealed significant improvement in clinical scores with hyaluronic scaffolds compared to microfracture alone. This study highlights the safety and positive clinical outcomes associated with the use of scaffolds for OCLT. In the few available comparative studies, scaffolds have also demonstrated superior clinical outcomes compared to microfractures alone. Nevertheless, the analysis has shown the limitations of the current literature, characterized by an overall low quality and scarcity of RCTs.
科研通智能强力驱动
Strongly Powered by AbleSci AI